West Pharmaceutical Services Inc. (NYSE:WST) Shares Sold by GW&K Investment Management LLC

GW&K Investment Management LLC reduced its holdings in West Pharmaceutical Services Inc. (NYSE:WST) by 0.1% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 343,932 shares of the medical instruments supplier’s stock after selling 252 shares during the period. GW&K Investment Management LLC owned approximately 0.46% of West Pharmaceutical Services worth $48,777,000 as of its most recent filing with the Securities & Exchange Commission.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Coldstream Capital Management Inc. grew its stake in West Pharmaceutical Services by 4.0% in the 2nd quarter. Coldstream Capital Management Inc. now owns 1,970 shares of the medical instruments supplier’s stock worth $246,000 after acquiring an additional 76 shares in the last quarter. Kings Point Capital Management raised its holdings in shares of West Pharmaceutical Services by 3.2% in the second quarter. Kings Point Capital Management now owns 2,864 shares of the medical instruments supplier’s stock valued at $358,000 after acquiring an additional 90 shares in the last quarter. Stephens Inc. AR lifted its stake in West Pharmaceutical Services by 3.0% in the second quarter. Stephens Inc. AR now owns 3,306 shares of the medical instruments supplier’s stock worth $414,000 after acquiring an additional 96 shares during the period. Cerebellum GP LLC lifted its stake in West Pharmaceutical Services by 4.1% in the third quarter. Cerebellum GP LLC now owns 3,060 shares of the medical instruments supplier’s stock worth $434,000 after acquiring an additional 121 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in West Pharmaceutical Services by 3.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,600 shares of the medical instruments supplier’s stock worth $652,000 after acquiring an additional 146 shares in the last quarter. Institutional investors own 90.21% of the company’s stock.

NYSE:WST opened at $149.43 on Tuesday. The firm has a market cap of $10.88 billion, a P/E ratio of 53.18, a price-to-earnings-growth ratio of 3.34 and a beta of 1.24. West Pharmaceutical Services Inc. has a 12 month low of $91.75 and a 12 month high of $152.10. The company has a current ratio of 3.00, a quick ratio of 2.31 and a debt-to-equity ratio of 0.17. The stock has a 50 day moving average of $145.39 and a two-hundred day moving average of $135.43.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, October 24th. The medical instruments supplier reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.08. West Pharmaceutical Services had a return on equity of 16.66% and a net margin of 12.82%. The firm had revenue of $456.10 million during the quarter, compared to the consensus estimate of $450.03 million. During the same period last year, the company earned $0.76 EPS. The company’s quarterly revenue was up 5.6% on a year-over-year basis. On average, research analysts forecast that West Pharmaceutical Services Inc. will post 3.14 earnings per share for the current year.

A number of brokerages recently weighed in on WST. Zacks Investment Research raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $160.00 price objective on the stock in a research report on Sunday, November 3rd. ValuEngine cut West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. West Pharmaceutical Services presently has an average rating of “Hold” and an average target price of $131.39.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, South Korea, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.

Featured Article: How is net asset value different from market price?

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Leave a Reply

Your email address will not be published. Required fields are marked *